Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells

Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells

In recent years, tyrosine kinase inhibitors (TKIs) have been shown capable of inhibiting the ATP-binding cassette (ABC) transporter-mediated multidrug resistance (MDR). In this study, we determine whether osimertinib, a novel selective, irreversible EGFR (epidermal growth factor receptor) TKI, could...

Full description

Bibliographic Details
Main Authors: Xiao-Yu Zhang, Yun-Kai Zhang, Yi-Jun Wang, Pranav Gupta, Leli Zeng, Megan Xu, Xiu-Qi Wang, Dong-Hua Yang, Zhe-Sheng Chen
Format: Article
Language:English
Published: MDPI AG 2016-09-01
Series:Molecules
Subjects:
osimertinib
multidrug resistance
ABCB1
tyrosine kinase inhibitors
Online Access:http://www.mdpi.com/1420-3049/21/9/1236

Internet

http://www.mdpi.com/1420-3049/21/9/1236

Similar Items